A number of classical articles on NPC suggest a dose–effect relationship for the primary tumor. Table 2 summarizes some of the frequently cited articles on local tumor control. The reported results GSK126 order concur with our findings: An EBT boost benefits particularly patients with NPC with early T-stage, that is, T1,2N+ tumors. For example, Teo et al. (10) showed a significant dose–tumor control

relationship at doses above the conventional tumoricidal dose levels for T1 and T2a tumor stages; their report justifies the use of an EBT boost as per protocol in the primary treatment program for NPC. Local tumor control is important as patients with an LR have an increased risk of M+; more so, although reirradiation in case of a relapse can be very helpful and therefore justified, it can also be associated with a high risk of complications. Wang (14) routinely included BT as a boost dose in the primary treatment: T1,2 tumors had a 5-year LR-free survival of 91% (with BT) vs. 60% (without BT). Chang et al. (15) demonstrated that BT had a significant impact on local control in

early-stage NPC. Levendag et al. (16) showed that a local control rate of www.selleckchem.com/products/Trichostatin-A.html 97% at 3 years can be reached with few complications using an EBT boost after a previous dose of 60–70 Gy. Leung et al. (17) showed that dose escalation beyond 66 Gy significantly improved the 5-year actuarial LR-free survival. In summary, some evidence in the literature, although being non-Class I evidence derived from nonrandomized data, points toward a beneficial effect, that is, a lower LRR with high doses of radiation in early-stage disease. In our article, in early-stage disease ( Table 2, T1,2N0 NPC, data derived from the Rotterdam and Amsterdam series), only one LR was found in the small cohort of the Rotterdam series (n = 8; using EBT boost) and one LR in the Amsterdam series (n = 11; no EBT boost). That is, no significant difference between both institutions was established. The

prime purpose of this article was to analyze in some detail the overall local control rate in advanced staged disease (T1,2N+ and T3-4N0,+ NPC) when randomized for a so-called second boost type technique by EBT. Most NPC patients present with advanced-stage disease: When comparing 34 T1,2N+ patients of the Rotterdam series Pyruvate dehydrogenase lipoamide kinase isozyme 1 with the 40 T1,2N+ patients of the Amsterdam series, no significant differences between the LRR in both institutions, that is, 0/40 (0%) vs. 4/40 (10%), respectively, could be observed (p = 0.058). Similar findings were found for T3,4N0,+ group of patients: 4/38 (11%; Rotterdsam series) vs. 4/36 (11%; Amsterdam series), respectively. With the current therapy, the local failure rate in early NPC disease (T1,2N0) is low (2/19; 11%). The third database, the Vienna protocol, designed by the International Atomic Energy Agency located in Vienna, consisted of 263 patients.